Our products

We offer a broad and differentiated portfolio of more than 670 products. It includes high-quality generic and branded generic medicines and a growing number of in licensed and specialty products.

3 Distinct businesses

Generic injectables manufacturing and supply in North America, Europe and MENA

Oral and non-injectables generic and specialty branded products manufacturing and supply in the US

Branded generic and in-licensed patented product in MENA

In the US, Hikma 503B provides outsourced sterile compounding services for injectables medicines. Discover more about 503B 

US

US

Canada

Canada

Europe

Europe

MENA

MENA

670+
Products on the market
32
Manufacturing plants
7
R&D centers worldwide

Related news

Hikma expands addiction therapy portfolio with the launch of Naloxone Hydrochloride Injection, USP, in prefilled syringe
4 January 2023
Hikma launches authorized generic of Xyrem® (sodium oxybate) in the US
3 January 2023
Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region
26 December 2022

Last reviewed on 30 May 2022